Crude Oil Gains 1.5%; ABM Posts Upbeat Q3 Earnings

ABM Isn’t Just Cleaning Buildings Anymore — Its Data Center Pipeline Is Multiplying

ABM stock jumps 7% after beating Q3 2026 earnings estimates, boosted by semiconductor and data center growth. Read the snapshot.

ABM Industries (ABM) Reports Q3 Earnings: What Key Metrics Have to Say

ABM Industries reported Q3 2026 revenue of $2.32 billion, up 4.2% year-over-year, beating consensus estimates by 0.71%. EPS of $1.04 exceeded expectations of $1.01 by 2.97%. Segment performance was mixed, with strong growth in Aviation (+12.4%) and Manufacturing & Distribution (+17.6%), offset by weakness in Business & Industry (-2.6%). The stock holds a Zacks Rank #3 (Hold) rating and has underperformed the S&P 500 over the past month.

ABM Industries (ABM) Q3 Earnings and Revenues Beat Estimates

ABM Industries reported Q3 2026 earnings of $1.04 per share, beating consensus estimates of $1.01, with revenues of $2.32 billion exceeding expectations by 0.71%. However, the stock has underperformed the S&P 500 year-to-date, gaining 11.2% versus the market's 12.8%. The company received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market. The Business - Services industry ranks in the bottom 24% of Zacks industries.

Novartis Myotonic Dystrophy Trial Flop Sends Dyne Therapeutics Shares Tumbling

Dyne Therapeutics stock sinks on Novartis' failed Phase 3 myotonic dystrophy study, even as Dyne prepares new trial data presentations.

Dyne Therapeutics shares are trading lower. The company announced it will present additional one-year Phase 1/2 ACHIEVE trial data for zeleciment basivarsen in DM1 at the 31st WMS Congress and the 2026 AANEM Annual Meeting.

Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session

U.S. stock futures fell as Novartis plunged 12.7% after pelacarsen’s Phase III trial missed its endpoint; other biotech stocks also declined.